for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

China Grand Pha.and Healthcare Hld. Ltd.

0512.HK

Latest Trade

4.53HKD

Change

-0.01(-0.22%)

Volume

3,900,000

Today's Range

4.50

 - 

4.61

52 Week Range

3.26

 - 

5.45

As of on the Hong Kong Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
4.54
Open
4.58
Volume
3,900,000
3M AVG Volume
41.76
Today's High
4.61
Today's Low
4.50
52 Week High
5.45
52 Week Low
3.26
Shares Out (MIL)
3,377.57
Market Cap (MIL)
15,300.40
Forward P/E
15.10
Dividend (Yield %)
--

Next Event

China Grand Pharmaceutical and Healthcare Holdings Ltd Annual Shareholders Meeting

Latest Developments

More

China Grand Pharmaceutical And Healthcare Obtains Medical Device Registration Certificate For Product

China Grand Pharmaceutical And Healthcare Says Grand Decade To Buy Stake In Oncosec Medical

China Grand Pharmaceutical And Healthcare HY Revenue Hk$3.59 Billion

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About China Grand Pha.and Healthcare Hld. Ltd.

China Grand Pharmaceutical and Healthcare Holdings Limited is a Hong Kong-based investment holding company principally engaged in the manufacture of pharmaceuticals. The main businesses of the Company include the research and development, manufacture and sales of pharmaceutical products, medical products, chemical products and healthcare products. The products of the Company include preparations, raw materials, medical devices, healthcare products, as well as agricultural and fine chemicals. Its products mainly focus on ophthalmic, cardiovascular and antibacterial, among others.

Industry

Biotechnology & Drugs

Contact Info

Units 3302

The Center, 99 Queen's Road Central

+852.2.8663718

http://www.chinagrandpharm.com

Executive Leadership

Chengwei Liu

Executive Chairman of the Board

Yan Shao

Chief Executive Officer, Executive Director

Bo Hu

Executive Deputy Chairman of the Board

Zhanqi Niu

Executive Director

Yonghua Feng

General Manager of Zhejiang Xianle

Key Stats

2.00 mean rating - 1 analysts
Sell
Hold
Buy
Revenue (MM, HKD)

2017

4.8K

2018

6.0K

2019(E)

7.2K
EPS (HKD)

2017

0.192

2019(E)

0.300
Price To Earnings (TTM)
14.69
Price To Sales (TTM)
2.42
Price To Book (MRQ)
1.93
Price To Cash Flow (TTM)
12.91
Total Debt To Equity (MRQ)
30.92
LT Debt To Equity (MRQ)
7.51
Return on Investment (TTM)
14.02
Return on Equity (TTM)
8.27

Latest News

Latest News

CORRECTED-BRIEF-Oncosec says China Grand Pharmaceutical And Healthcare Holdings to invest $30 Mln in Co

* ONCOSEC ANNOUNCES $30 MILLION USD STRATEGIC INVESTMENT AT A PREMIUM TO MARKET BY CHINA GRAND PHARMACEUTICAL AND HEALTHCARE HOLDINGS (CGP) IN CONNECTION WITH EXCLUSIVE LICENSE TO TAVO™ IN GREATER CHINA AND 35 OTHER ASIAN COUNTRIES

CORRECTED-BRIEF-Sirtex Medical Notes Announcement By China Grand Pharmaceutical And Healthcare Holdings

* NOTES AUG 17 ANNOUNCEMENT BY CHINA GRAND PHARMACEUTICAL AND HEALTHCARE HOLDINGS LTD

BRIEF-China Grand Pharmaceutical and Healthcare Holdings says to establish JV co

China Grand Pharmaceutical And Healthcare Holdings Ltd

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up